Cyclacel Pharmaceuticals (CYCC) received a written notice from The Nasdaq Stock Market granting the Company an extension until December 24, 2024, to regain compliance with Nasdaq’s minimum stockholders equity requirement under Nasdaq Listing Rule 5550(b)(1). This Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. As previously reported, on August 26, 2024, the Listing Qualifications Staff of Nasdaq determined that the Company was not in compliance with the Equity Standard Rule because the Company reported stockholders’ equity of less than $2.5 million as of June 30, 2024.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYCC:
- Roth MKM downgrades Cyclacel to Neutral after ‘not encouraging’ data
- Cyclacel Pharmaceuticals downgraded to Neutral from Buy at Roth MKM
- Cyclacel reports clinical data from Phase 2 study of oral fadraciclib
- Biotech Alert: Searches spiking for these stocks today
- Cyclacel Pharmaceuticals files to sell common stock, warrants, no amount given